Abstract
Two large, independent human immunodeficiency virus type 1 resistance databases containing >7700 reverse-transcriptase (RT) sequences were used to analyze the epidemiology of amino acid substitutions at codons 44 and 118, which confer moderate lamivudine resistance in the presence of zidovudine resistance. As expected, E44A/D and V118I mutations were strongly associated with M41L, D67N, L210W, and T215Y but also with other mutations, including K43E/N/Q, T69D, V75M, H208Y, R211K, and K219R. Both E44D and V118I were more frequently associated with stavudine and didanosine than with zidovudine and lamivudine treatment. However, selection of E44A/D and V118I was also detected in association with a switch to other nucleoside RT inhibitors, including zalcitabine and abacavir. Site-directed mutagenesis confirmed that 44D and 118I can decrease phenotypic susceptibility not only to lamivudine but also to most other nucleoside analogues, particularly stavudine and abacavir. Thus, substitutions at RT codons 44 and 118 have broad implications in nucleoside RT inhibitor resistance in the setting of several nucleoside-associated mutations.
Citations
Mar 12, 2004·International Journal of Antimicrobial Agents·M C ReUNKNOWN HIV-1 Emilia Romagna Infectious Disease Study Group
Sep 21, 2010·Nature Structural & Molecular Biology·Xiongying TuEddy Arnold
Oct 25, 2008·Nucleic Acids Research·Na LiAndrew D Ellington
Jan 16, 2008·AIDS·Christos MihailidisAnton Pozniak
Feb 18, 2010·AIDS·Jessica RadzioNicolas Sluis-Cremer
Nov 19, 2002·Antimicrobial Agents and Chemotherapy·Thomas C StoeckliDaniel R Kuritzkes
Oct 27, 2004·Antimicrobial Agents and Chemotherapy·Marco PetrellaMark A Wainberg
Dec 18, 2012·Journal of Clinical Microbiology·Moussa ThiamCoumba Toure-Kane
Jul 5, 2003·Journal of Clinical Microbiology·R A GalliP R Harrigan
Jul 1, 2006·Journal of Virology·Valentina SvicherCarlo Federico Perno
Jul 30, 2011·PloS One·Dieter HoffmannWalid Heneine
Jan 14, 2003·Pharmacotherapy·Tony AntoniouAlice L Tseng
Jun 30, 2007·Drugs·Santiago MorenoFernando Dronda
Oct 22, 2002·Expert Opinion on Biological Therapy·Bluma G BrennerMark A Wainberg
Jun 25, 2009·Antiviral Research·Laura MonnoGioacchino Angarano
May 12, 2009·Antiviral Research·Atsuko HachiyaShinichi Oka
Feb 15, 2008·Virus Research·Luis Menéndez-Arias
Jul 19, 2005·Virus Research·D ParaskevisUNKNOWN Hellenic Multi-centre study on HIV-resistance
Jun 28, 2013·The Journal of General Virology·Jiong WangCarrie Dykes
Dec 7, 2007·PLoS Medicine·Soo-Huey YapGilda Tachedjian
Apr 13, 2011·PloS One·Javier P MartínezAndreas Meyerhans
Dec 8, 2004·Current Opinion in Structural Biology·Stefan G SarafianosEddy Arnold
Nov 16, 2005·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Ruengpung SutthentSombat Tanprasertsuk
Nov 22, 2008·Journal of Molecular Biology·Stefan G SarafianosEddy Arnold
May 3, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Nicola GianottiAntonella Castagna
Sep 26, 2006·Journal of Medical Virology·W M NadembegaS Musumeci
Jun 24, 2003·The Journal of Biological Chemistry·Mélanie GirouardMatthias Götte
Jan 7, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Chris BirchSean Emery
Aug 2, 2003·AIDS·Françoise Brun-VézinetUNKNOWN Narval (ANRS 088) Study group
Mar 16, 2007·The Journal of Antimicrobial Chemotherapy·G NebbiaUNKNOWN UK Collaborative HIV Cohort (CHIC) Study Group